NEW YORK (GenomeWeb News) – German chemical proteomics firm Cellzome said today that it has hit a second milestone in its ongoing epigentics collaboration with GlaxoSmithKline.
The firm did not disclose the amount of the payment, but said that it comes only two months after the firm achieved a first milestone in the collaboration.
As GenomeWeb Daily News reported in early 2010, GSK paid €33 million ($45 million) up front for exclusive access to Cellzome's Episphere for epigenetic research on immunoinflammatory disease. Cellzome could be eligible for milestone payments of over €475 million, the firms said at the time.
"Achieving the second milestone in this collaboration in less than a year after its start demonstrates how well our technology is suited to address drug discovery for epigenetic targets," Cellzome CEO Tim Edwards said in a statement.